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ABSTRACT 
Positron emission tomography (PET) is a molecular imaging technique that 
allows for examinations of neurochemistry directly in the living human brain. 
In the present thesis, PET was used to assess the pharmacological effects of 
two drugs representing the major classes of antipsychotic and antidepressant 
drugs.  In addition, novel methodology for studies on antidepressant 
mechanism of action was developed further.  
 In study I, striatal D2 dopamine receptor occupancy was 
examined in healthy subjects after administration of the antipsychotic drug 
quetiapine in two formulations, immediate-release (IR) and extended-release 
(XR), respectively. The D2 occupancy at peak concentration was higher for the 
IR compared to the XR formulation (50±4% and 32±11% respectively). The 
result may explain observed pharmacodynamic differences between the two 
formulations, and also support the view that quetiapine may show 
antipsychotic effect at lower D2 receptor occupancy than the first-generation of 
antipsychotic drugs.     
 In study II, changes in serotonin concentration were assessed in 
healthy subjects after administration of a single, clinically relevant dose of the 
antidepressant drug escitalopram. A competition-model with the 5-HT1B 
receptor selective radioligand [11C]AZ10419369 was used to indirectly 
measure changes in extracellular endogenous serotonin concentration after 
drug administration. Escitalopram was found to decrease serotonin 
concentrations in serotonergic projection areas. This observation directly in 
human subjects extends previous hypotheses on the mechanism of action of 
antidepressant drugs, derived primarily from experimental animals.   
  The aim of study III was primarily to evaluate the methodology 
of study II. The binding potential of the radioligand [11C]AZ10419369 was 
determined in two consecutive PET measurements, performed on the same day 
in 8 healthy subjects. In serotonergic projection areas the mean difference in 
radioligand binding between PET 1 and PET 2 was minor, supporting the 
methodology and interpretation of the results of study II.  
  In study IV, the effect of age on 5-HT1B receptor availability was 
examined. The 5-HT1B receptor availability decreased significantly with age in 
cortical regions. On the contrary, the 5-HT1B receptor availability in the 
caudate nucleus and the putamen remained stable over the investigated age 
range. This observation may indicate that the 5-HT1B receptors in these regions 
are expressed on neurons with a different sensitivity to aging. The results 
highlight the importance of using age-matched controls in future clinical 
studies on the 5-HT1B receptor. 
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1 INTRODUCTION 
It is estimated that the human brain contains between 20 and 100 billion nerve 
cells (neurons). The neurons are organized in different groups and circuits, of 
which some remain to be identified. A neuron consists of a cell body (soma); 
dendrites which receives information from other neurons; and an axon which 
upon activation sends information to other neurons via a conjunction called the 
synapse. At activation a neuron-specific neurotransmitter such as dopamine or 
serotonin, is released from the terminal of the axon. The neurotransmitter passes 
the synaptic cleft and in many cases delivers a message to a receptor on the other 
side of the synapse, i.e. on the post-synaptic neuron (Figure 1). 
 
 
 
Figure 1: Scematic illustration of a synapse 
 
It has been estimated that each neuron on average has contact with 10.000 other 
neurons. Thus, in each individual brain, there are trillions of connections 
between nerve cells. Although the understanding of the central nervous system 
(CNS) has greatly improved during last decades, much of the organization and 
functional role of the neurotransmission systems is still not fully understood.  For 
instance, genes encoding for over 700 G protein-coupled receptors have been 
identified in the human genome [1], but the function of many of these receptors 
remains to be clarified. Further, the regulation of the expression of these 
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receptors is only partly understood, as is their functional role in relation to 
human behavior.   
The majority of pharmacological treatments for psychiatric disorders are 
targeting receptors, transporters or enzymes of the brain neurotransmission 
system. Initially such drugs were discovered through empirical observations, and 
their mechanism of action (MoA) was not defined until later. Nowadays, drugs 
are instead developed in a more rational fashion, to match current hypothesis of 
the pathophysiology of psychiatric disorders. However, a bottleneck for such 
developments is that the pathophysiology of major psychiatric disorders such as 
schizophrenia still remains largely unknown.  
 
With the advent of positron emission tomography (PET) in the late 1970´s, it 
became possible to examine neuro-chemistry directly in the living human brain. 
PET has subsequently been applied to examine both the normal functioning of 
the CNS, the pathophysiology of psychiatric diseases as well as the molecular 
effects of drugs targeting the CNS [2]. In the present thesis, PET was used to 
assess the MoA of two drugs representing the major classes of antipsychotic and 
antidepressant drugs. To allow for studies on antidepressant MoA, the thesis 
includes examination of new methodology. 
 
1.1 POSITRON EMISSION TOMOGRAPHY 
1.1.1 General 
PET is an imaging technique that allows for examinations of biochemistry and 
metabolism in vivo. The present thesis is focusing on the use of PET for 
examinations of biomarkers of neurotransmission in brain. 
Crucial for the use of PET, is the development and availability of suitable 
positron-emitting radiotracers. While most PET radiotracers are receptor ligands 
that have been developed to bind to a specific target molecule in the brain, other 
tracers allow for measurements of blood flow or metabolic activity. Typically, 
radioligands intended for brain examinations are designed to fit the binding 
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pocket of a receptor, transporter or enzyme, with high selectivity. PET 
radioligands are commonly labeled with a short-lived radionuclide such as 11C 
(half-life (t½) = 20.3 min) or 18F (t½ = 110 min).  
 
In a typical PET measurement, the radioligand is injected into a vein, and 
distributed to the brain via the blood stream. After passage over the blood brain 
barrier (BBB), the radioligand binds to the target molecule in brain. At decay of 
the radionuclide, a positron is emitted. The positron travels a short distance in the 
brain tissue (for 11C typically about 1 mm) [3], until it collides with an electron. 
In the annihilation that follows, two gamma-particles (photons) are generated. 
The two photons move away from the site of annihilation in approximately 
opposite directions (i.e. 180±0.25o) [4], and are eventually detected by the PET 
system (Figure 2). When two photons arrive at two detectors within a short 
timeframe at an angle of 180o, they are registered as a coincidence event. During 
a PET measurement, a large number of such coincidences are collected. The 
coincidences are subsequently used to reconstruct a 3D representation of the 
radioactivity distribution in the brain. The reconstruction process includes 
corrections for errors in the data collection procedure, such as scatter and random 
coincidences [3]. 
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Figure 2. Schematic figure illustrating the collision between the positron (p+) 
emitted at decay of the radionuclide, and an electron (e-) within the brain tissue. 
As indicated by the broken line, the two photons generated move away from the 
site of annihilation and are eventually detected by the PET system (Figure made 
with help of Martin Schain) 
 
Spatial resolution can be described as the ability of a system to distinguish small 
structures as separate units. The smallest structures that can be separated define 
the resolution of the system. The PET system used in the present thesis, the High 
Resolution Research Tomography (HRRT; Siemens Molecular Imaging, USA), 
is dedicated for imaging of the CNS. The HRRT system has the highest 
resolution (approximately 1.5 mm) of all presently available PET systems for the 
human brain [5]. Thus, the HRRT system can be used to examine also small sub-
regions of the brain.  
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1.1.2 Principles for applied PET studies 
Radioligand binding to receptors, transporters or enzymes can be viewed as 
potential biomarkers of disease. Over the years, a large number of PET studies 
have been reported, addressing changes in such biomarkers in psychiatric 
disorders. Among the neurotransmission systems, the dopamine and serotonin 
systems have been the most extensively examined. While there is still no 
consensus regarding clinical use of biomarkers in psychiatric disorders, a more 
accepted disease biomarker is the beta-amyloid protein, which is expressed in 
high densities in patients with Alzheimer’s disease [6]. 
PET can also be used in several steps of drug discovery and development [2]. 
Crucial for the effect of a neuropsychiatric drug is that it reaches the intended 
target in the brain. In the early stages of drug development, passage over the 
BBB in humans can be assured, by injection of a micro dose of the radiolabeled 
drug. This methodology can be very time- and cost-saving, as drugs shown not 
to pass the BBB can be discarded from further development at an early time. 
PET can also be used to assure that the drug binds at the aimed target. This is 
usually established in two steps: First, a baseline PET measurement with a 
radioligand with confirmed binding to the target is performed. Then, a second 
PET measurement with the same radioligand is performed after administration of 
the drug. The difference in binding potential between PET 1 and PET 2 can be 
used to estimate the fraction of the target molecules that are occupied by the 
drug. This methodology can also be extended to cover the relationship between 
dose/plasmaconcentration of the drug and receptor occupancy in brain. 
In patients, receptor occupancy in brain can be related to the clinical effect of the 
drug. This approach was early applied to define a therapeutic window for 
optimal dopamine D2 receptor occupancy during treatment with antipsychotic 
drugs [7] .  
 
1.2 BRAIN NEUROTRANSMISSION SYSTEMS 
Most brain neurotransmission systems are defined by endogenous 
neurotransmitters. Approximately 100 neurotransmitters have been identified, 
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including peptides and hormones. The neurotransmitter-receptors can be divided 
in two major groups. G-protein coupled receptors are coupled to G proteins, 
which can stimulate or inhibit enzymes to produce a second messenger substance 
within the cell [8]. Other receptors are protein complexes forming ligand-gated 
ion-channels in nerve cell membranes, and regulate the opening and closing of 
the ion channel at activation. When an ion-channel receptor is activated, the 
effect is more or less immediate (< 1 millisecond), whereas the effect of 
activation of a second-messenger receptor is more slow (hundreds of 
milliseconds up to minutes) [9].  
 
1.2.1 Monoamine neurotransmitters 
Monoamine neurotransmitters are defined by their molecular properties, i.e. they 
are transmitters that contain an amine group connected to an aromatic ring. 
Dopamine, noradrenaline, histamine and serotonin are four examples of 
monoamine neurotransmitters that are of central importance for the human brain. 
These four monoamine transmitter systems share some common features. The 
cell bodies of the neurons are mainly located in the brain stem, from where they 
project axons to different parts of the brain, including the neocortex. The present 
thesis addresses aspects of two of the monoaminergic neurotransmitter systems, 
namely the dopamine and the serotonin system.  
 
1.2.2 Dopamine 
Dopamine was initially considered to be merely an inactive precursor of 
noradrenaline. During the 1950´s, experiments with reserpine were performed, to 
deplete catecholamine stores in animals. Arvid Carlsson and coworkers 
administered 3,4-dihydroxyphenylalanine (DOPA) to reserpine-treated rabbits, 
to replenish what was thought to be the noradrenaline stores. The DOPA 
administration reversed the reserpine-induced sedation and hypokinesia of the 
rabbits [10]. However, when brain tissues from these animals were analyzed, it 
was discovered that the tissue was still fully depleted of noradrenaline. Further 
experiments demonstrated that the anti-reserpine action of DOPA on animal 
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behavior was correlated to the restoration of dopamine levels in the brain [11, 
12]. Subsequently, these results led to the suggestion that dopamine also is a 
neurotransmitter (For review, see [13]). 
 
1.2.2.1 The dopamine system 
The dopaminergic cell bodies are mainly located in the brain stem, within the 
substantia nigra and the ventral tegmental area (VTA). Three different 
dopaminergic pathways arise from these cell bodies [14] (for review see [15]): 
1. The nigro-striatal pathway, with cell bodies in substantia nigra projecting to 
dorsal striatum [16]. This pathway has since long been known to be involved 
in motor function [17]. More recently involvement also in cognitive function 
have been described [18]. 
2. The mesolimbic pathway, with cell bodies in VTA projecting to nucleus 
accumbens and other parts of the limbic system. This pathway is thought to 
be involved in emotional processing, reward and motivation [17].  
3. The mesocortical pathway (from VTA to frontal cortex), which might be 
involved in cognitive function and affective regulation [17].  
A fourth pathway has its origin in the hypothalamus and regulates secretion of 
the hormone prolactin in the anterior pituitary gland. This pathway is called the 
tuberoinfundibular pathway [17]. 
A fifth dopaminergic pathway has recently been described in primates. This 
pathway arises from multiple sites within the upper brain stem and hypothalamus 
and projects to the thalamus [19]. The function of this thalamic pathway is not 
yet known, but it has been hypothesized to be involved in emotion, attention, 
cognition and motor control [20]. 
 
1.2.2.2 Dopamine synthesis and degradation 
Dopamine does not pass the BBB, and is synthesized within the brain from the 
amino acid tyrosine. Initially, tyrosine is converted into L-DOPA by the enzyme 
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tyrosine hydroxylase. L-DOPA is further converted to dopamine by DOPA 
decarboxylase. The synthesized dopamine is stored into synaptic vesicles, where 
it remains until it is released into the synaptic cleft following neuronal firing 
[17].  
After release, dopamine can travel across the synaptic cleft and reach receptors 
on the post-synaptic neuron. The activity of the released dopamine is mainly 
terminated by re-uptake into the releasing dopamine neuron by a presynaptic 
transporter (the DAT). Inside the dopamine neuron, dopamine can again be 
stored in synaptic vesicles for future use. Intra-neuronal dopamine that is not 
stored in synaptic vesicles is enzymatically degraded by monoamine oxidase A 
(MAO-A) or MAO-B. Extracellular dopamine can be degraded outside the 
neuron by the enzyme catechol-O- methyl transferase (COMT). Dopamine can 
also diffuse away from the synapse and be transported into noradrenergic 
neurons by the noradrenergic transporter (NET) [17].  
 
1.2.2.3 Dopamine receptors     
Five different dopamine receptor subtypes have been described and assigned 
numbers from D1 to D5.  Depending on their coupling to second messenger 
systems, they have been further categorized into two families: The D1-like 
family and the D2-like family. The D1 family comprises the D1 and the D5 
receptor, and the D2 family includes the D2, D3 and D4 receptors. All dopamine 
receptors are G protein-coupled. The D1-receptor family is coupled to Gs-type G 
proteins that activate adenylyl cyclase enzymes to synthesize cyclic adenosine 
monophosphate (cAMP), and the D2-receptor family are coupled to Gi- and 
Gotype -proteins that inhibit adenylyl cyclase and cAMP formation [21].  
Each of the five receptors has its own unique distribution in the brain. The D1 
subtype is the most abundant dopamine receptor in the human brain [21]. 
Despite this, the D2 receptor, being a target for antipsychotic drugs, is probably 
the most extensively studied of the five dopamine receptor subtypes. 
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1.2.2.4 The D2 receptor 
The highest density of the D2 receptor is found in the striatum [22]. The D2 
receptor exists in a short and a long isoform – D2S and D2L [23]. The D2L is 
located mainly postsynaptically and the D2S is found mainly as a presynaptic 
auroreceptor on the dopamine neurons [24, 25]. The D2 autoreceptor inhibits the 
release of dopamine and is situated both at the somatodendritic area of the 
dopamine neuron, and at the axon terminal. However, the largest amount of D2 
receptors is located at the post-synaptic side of the dopamine neuron.   
 
1.2.2.5 Radioligands for the D2 receptor 
The first measurement of D2 receptors in the living human brain was made in 
1983 by Wagner and coworkers, using [11C]N-methyl-spiperone and PET [26]. 
As methyl-spiperone binds also to 5-HT2 receptors, there was a need for 
radioligands with a more selective binding to the D2 receptor. [11C]Raclopride, 
developed in the mid-1980´s [27] is selective for the D2 and D3 receptor, and is 
currently the most used radioligand for PET imaging of D2 receptors. However, 
the affinity of [11C]raclopride is not sufficiently high for measurements of 
extrastriatal D2 receptors, which are expressed at low densities. For this purpose, 
[11C]FLB457 [28] and [18F]fallypride [29] have been developed.   
 
1.2.3 Serotonin 
The substance nowadays referred to as serotonin, was identified in the 
gastrointestinal system of animals in 1937, and denominated enteramine (for 
review, see [30]). About a decade later, a vasoconstrictive substance was isolated 
in serum, and named serotonin [31]. In 1952 it was uncovered that enteramine 
and serotonin indeed were the same substance [32]. Serotonin was eventually 
detected also in the CNS [33] and following studies could confirm its function as 
a neurotransmitter in the brain [34, 35]. 
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1.2.3.1 The serotonin system in the CNS 
The first anatomical description of serotonin pathways in the CNS was published 
in 1964 [36]. The serotonergic cell bodies are located in the brain stem, in small 
clusters referred to as the raphe nuclei. Their axons project to basically all parts 
of the brain as well as to the cerebellum and the spinal cord, making the 
serotonin system influential on several physiological functions.  
Among the raphe nuclei, the dorsal and median raphe nuclei are the primary 
nuclei for serotonergic innervation of the brain [37-39]. 
 
1.2.3.2 Serotonin synthesis and degradation 
Serotonin, just as dopamine, does not pass the BBB, and is synthesized within 
the brain from the amino acid tryptophan, which is transported from the plasma 
into the brain. Inside the serotonin neuron, tryptophan is converted into 5-
hydroxy-tryptophan via the enzyme tryptophan hydroxylase. Then, 5-
hydroxytryptophan is converted to serotonin via another enzyme, the aromatic 
amino acid decarboxylase.  Like dopamine, serotonin is stored in synaptic 
vesicles until it is released for neurotransmission [17].  
The activity of a released serotonin molecule is terminated by re-uptake into the 
serotonergic neuron by the serotonin transporter (SERT or 5-HTT) or by 
enzymatic degradation by MAO-A. After re-uptake into the serotonin neuron, 
serotonin can again be stored in synaptic vesicles for future use [17]. 
 
1.2.3.3 Serotonin receptor subtypes 
To date, 14 serotonin receptor subtypes have been identified in humans. All of 
these are G protein-coupled receptors, except for the 5-HT3 receptor, which is an 
ion channel linked receptor [40-42]. 
Two of the receptor subtypes act as autoreceptors. The 5-HT1A receptor is 
located at the somatodendritic area of the serotonin neuron in the raphe nuclei 
and regulates the firing rate of the serotonin neurons. The 5-HT1B receptor is 
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located at axon terminals, and regulates the release of serotonin at the pre-
synaptic level.  
 
1.2.3.4 The 5-HT1B receptor 
The nomenclature for the human 5-HT1B receptor has been confusing. Initially, 
the human 5-HT1D receptor was considered to be an equivalent of the 5-HT1B 
receptor in rodents. The human 5-HT1D receptor was later found to have two 
isoforms, 5-HT1Dα and 5-HT1Dβ. It was eventually demonstrated that the receptor 
defined as human 5-HT1Dβ, is the species equivalent of the rodent 5-HT1B 
receptor. Thus, the human 5-HT1Dβ receptor was re-named to 5-HT1B, and the 
human 5-HT1Dα was called 5-HT1D without further subdivision (for review 
see[40].  
The 5-HT1B receptor functions both as an autoreceptor as described above, and as 
a heteroreceptor, regulating the release of other neurotransmitters. Thus, it is 
expressed by both serotonin and non-serotonin cell populations. The highest 
densities of the 5-HT1B receptor are found in the globus pallidus and substantia 
nigra; lower densities are found in striatum, cortical regions, amygdala, 
hippocampus, hypothalamus and thalamus [43]. 
The 5-HT1B receptor has gained particular interest lately, as it has been 
implicated in both normal physiology and several psychiatric and somatic 
disorders. For example, the 5-HT1B receptor is considered to participate in the 
regulation of locomotion, feeding behavior, sleep, aggression and impulsivity 
(for review see [44] and [45]). A specific role of 5-HT1B in the pathophysiology 
of anxiety and depression (for review see [45]), as well as in Parkinson´s disease 
[46, 47] has also been suggested.  
 
1.2.3.5 Radioligands for the 5-HT1B receptor 
Currently, only two 5-HT1B receptor selective PET radioligands have been 
evaluated in human subjects: [11C]AZ10419369 [48] (used in the present thesis) 
and [11C]P943 [49].  However, in the development of [11C]AZ10419369,  a total 
 12 
of eight radioligands were evaluated as potential PET radioligands for the 5-
HT1B receptor, in non-human primates [50]. As [11C]AZ10419369 provided 
highest regional contrast, this radioligand was selected for further evaluation in 
human subjects [51].  
The use of a competition-model with radioligands selective for the D2 receptor is 
a well-recognized method for indirect measurements of endogenous extracellular 
dopamine levels [52, 53] (for review see [54]). A method for similar 
measurements of extracellular concentrations of endogenous serotonin in vivo 
has previously not been available. It is believed that autoreceptors – compared to 
heteroreceptors – may be particularly sensitive to their endogenous 
neurotransmitter. Therefore the two radioligands developed for the 5-HT1B 
receptor have also been tested for their sensitivity to endogenous serotonin 
levels. Indeed, both [11C]AZ10419369 [55, 56] and [11C]P943 [57] have proven 
sensitive to changes in serotonin levels in non-human primates. 
 
1.3 EXAMPLES OF PSYCHIATRIC DISORDERS RELATED TO 
MONOAMINERGIC NEUROTRANSMISSION AND THEIR 
TREATMENTS 
1.3.1 Schizophrenia  
Schizophrenia is a thoroughly disabling psychiatric disease, that affects 
approximately 0.5- 1 % of the population worldwide.  Symptoms usually appear 
early in life, typically between age 16-30, and the disorder is life-long. The 
prevalence in men and women is equally high, but men tend to get the disease at 
an earlier age and have a worse outcome. The etiology of schizophrenia is 
unknown, but both genetic and environmental risk factors have been identified 
(for review see [58, 59]). 
 
Schizophrenia symptoms are usually divided into positive, negative and 
cognitive symptoms.  Positive symptoms are hallucinations, delusions and 
bizarre behavior. Negative symptoms include blunted affects, anhedonia and 
apathy. Although negative symptoms are less obvious than the positive ones, 
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negative symptoms are closely correlated to poor psychosocial functioning. 
Deficits in cognitive functions are common in schizophrenia, and may affect all 
cognitive domains. The cognitive deficits are also strongly correlated to 
functional outcome (for review see [58, 59]). 
 
1.3.1.1 The dopamine hypothesis of schizophrenia 
The dopamine hypothesis of schizophrenia was initially founded based on the 
discovery that antipsychotic agents block dopamine receptors  [60, 61], and that 
dopamine-releasing drugs can induce psychotic symptoms [62]. Therefore, it 
was proposed that patients with schizophrenia have a hyperactive dopamine 
system. However, the hypothesis has later been revised, postulating that the 
dopamine system in schizophrenia patients is both hyper- and hypo-active, in 
different brain regions. Positive symptoms are assumed to be related to a 
hyperactivity of dopamine transmission in the mesolimbic pathway, and negative 
and cognitive symptoms are assumed to be related to an hypoactivity in the 
mesocortical system [63]. 
Direct evidence for an increased dopamine transmission in the striatum of 
schizophrenia patients, has been gained from brain imaging studies. When 
exposed to amphetamine (a dopamine releasing agent), patients with 
schizophrenia show a more pronounced reduction in radioligand binding to D2 
receptors than healthy controls. The interpretation is that amphetamine causes a 
larger increase of dopamine in patients with schizophrenia [64-66]. Some studies 
have also shown that the increase in dopamine is related to emergence or 
worsening of positive symptoms [65, 66].  
 
1.3.2 Antipsychotics 
The first antipsychotic drug – chlorpromazine - was discovered empirically in 
1952 (for review see [67]) and its mechanism of action was initially entirely 
unknown. In the mid 1960´s, it was suggested that antipsychotic drugs act by 
blocking dopamine receptors [60, 61]. A decade later, a close correlation 
between D2 receptor affinity in vitro and clinical antipsychotic effect could be 
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shown for a series of antipsychotic drugs [68, 69]. Further on, it was also 
demonstrated that antipsychotic drugs bind primarily to the dopamine D2 
receptor subtype [70].  The results were subsequently verified also in vivo, when 
high occupancy of D2 receptors could be demonstrated in patients treated with 
antipsychotic drugs [71-74]. 
Traditionally, antipsychotics have been classified into two major groups: 
“typical” and “atypical” antipsychotics. The “typical” antipsychotics were all 
known to cause extrapyramidal side-effects (EPS) and raised serum prolactin 
levels. Clozapine, introduced in the early 1970´s, was the first “atypical” 
antipsychotic drug (for review see [75]). The term “atypical” initially referred to 
antipsychotic drugs not causing EPS or prolactin elevations, but the atypicality 
concept has later been widened. Currently there is no consensus on the definition 
of an “atypical” antipsychotic drug, but most pharmacologists and psychiatrists 
still seem to agree that a lower risk for EPS and prolactin elevations is a common 
property of “atypical” antipsychotics.  
A number of new antipsychotics have been introduced on the market following 
clozapine. While all of these have been discussed as being “atypical”, the term 
“second-generation” antipsychotic has also been used for the more recently 
introduced drugs. To explain the lower risk of EPS with these compounds, 
several hypotheses have been proposed. One hypothesis is based on the 
observation that all second-generation drugs have antagonistic effect on the 5-
HT2A receptor. Experimental studies have shown that the blocking of 5-HT2A 
receptors enhance dopamine release in striatum, thereby counteracting the effect 
of the D2 antagonism in this regions (for review see [76]).  
In addition to EPS, antipsychotic drugs also have other severe side effects. 
Sedation, cardiac side effects (prolonged QT interval) and anticholinergic side 
effects are a few of these, and particularly second-generation drugs are 
associated with metabolic side effects. For clozapine, the risk of agranulocytosis 
limits its more widespread use. Another well-recognized problem in 
schizophrenia treatment is that cognitive and negative symptoms usually respond 
poorly to antipsychotic drugs (for review see [77]). 
Although all antipsychotic drugs – both typical and atypical - bind to the D2 
receptor, most of them have affinity also to several other receptors. It has not yet 
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been conclusively demonstrated whether any of these receptors contribute to the 
antipsychotic effect.  
 
1.3.2.1 D2 dopamine receptor occupancy 
All currently available antipsychotic drugs are antagonists or partial agonists at 
the D2 receptor. Based on results from PET studies on patients with 
schizophrenia, a therapeutic window corresponding to approximately 65-80% 
striatal D2 occupancy has been suggested. Even though the exact lower limit of 
this window has been difficult to define, occupancy above 80% is rather 
consistently related to extrapyramidal side effects [78-80] (Figure 3). Indirect 
support for an efficacy threshold around 65-70% D2 occupancy, is provided by 
reports that clinical doses of more recently developed drugs also correspond to 
this occupancy level [81-86]. 
 
 
Figure 3: Relationship between dose/plasma concentration (arbitrary values) 
and striatal D2 receptor occupancy with suggested thresholds for antipsychotic 
effect and extrapyramidal side effects (EPS). (Figure modified from Farde L, 
Trends Neurosci 1996 (6)).  
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However, there are also drugs that do not fit this therapeutic window. First, D2 
occupancy during treatment with clinical doses of the antipsychotic drug 
aripiprazole, exceeds the therapeutic window [87-89]. However, as aripiprazole 
is a partial agonist at the D2 receptor - in contrast to other antipsychotics that are 
antagonists – the high D2 occupancy is thought to be functionally compensated 
for by a modest intrinsic activity [90]. 
Second, D2 occupancy during clinical treatment with the atypical antipsychotic 
drug clozapine, is below the suggested therapeutic window [78, 91-93]. This is 
particularly intriguing, since clozapine despite lower D2 occupancy has been 
shown to have superior efficacy in patients refractory to other antipsychotic 
drugs [94] (for review see [95]).  
An unsolved question is whether high D2 occupancy needs to be maintained 
during a certain time for mediation of antipsychotic effect. In initial studies of 
first-generation antipsychotics, high D2 occupancy has been shown to be 
maintained throughout the dosing interval after oral administration [96-98]. 
Several second generation drugs have also been shown to maintain D2 occupancy 
at rather stable levels throughout the dosing interval [99]. However, during 
maintenance treatment with injectable haloperidol in a depot formulation, it has 
been shown that relapse can be prevented despite moderate or low D2 occupancy 
at the end of the four-week dosing interval  [100]. Comparable results have been 
achieved in a study with risperidone in a depot formulation [101]. However, a 
fundamental question is whether the same time course of occupancy is required 
to prevent relapse as to treat acute psychosis. 
 
1.3.2.2 Quetiapine 
Quetiapine (QTP) is a second-generation antipsychotic drug, approved in 1997 
[102]. The clinical effects are thought to be mediated both by QTP and its main 
active human metabolite nor-quetiapine [103]. Interestingly, like clozapine, QTP 
has been shown to induce D2 receptor occupancy below the therapeutic window 
when administered in recommended doses [104-106]. It is possible that the low 
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D2 occupancy can explain the low risk of EPS during quetiapine treatment  
[107]. However, quetiapine has a short elimination half-life and only transiently 
high plasma concentration [108]. It can thus not be excluded that maximal D2 
occupancy, estimated by PET during quetiapine treatment, has been 
underestimated [109, 110].  
 
1.3.3 Depression 
Depression is a common psychiatric disorder, with a life-time incidence of 10-20 
%. Depression is almost twice as common in women compared to men (for 
review see [111]). The symptom severity can range from mild to very severe. As 
for schizophrenia, both genetic and environmental variables have been identified 
as risk factors for depression. Worth noting is that the genetic component may be 
smaller in depression compared to schizophrenia [111]. 
The diagnosis of depression (or more correctly “Major Depressive Disorder”, 
MDD) [112] is based on the presence of several symptoms, with duration of at 
least two weeks. The main symptoms are depressed mood and anhedonia, but 
associated symptoms such as appetite or sleep disturbances; psychomotor 
changes; fatigue; diminished ability to concentrate; feelings of worthlessness or 
excessive guilt; and suicidal thoughts or attempts are also included in the 
diagnostic criteria.  
 
1.3.3.1 The serotonin hypothesis of depression 
The serotonin hypothesis of depression was introduced in the 1960s. The 
hypothesis was initially based on the finding that both tricyclic antidepressants 
(TCAs) and MAO inhibitors (MAOIs) increase the synaptic availability of 
serotonin. This observation lead to the assumption that reduced serotonin 
transmission had a causative effect in depression. The fact that clinically 
effective antidepressants affect the serotonin system is still one of the strongest 
arguments for the involvement of the serotonin system in depression.  
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Several other lines of evidence also support serotonergic involvement in 
depression.  
For instance, already in the 1960´s, concentrations of serotonin and its metabolite 
5-HIAA post-mortem were reported to be lower in depressed patients that had 
committed suicide, than in victims of sudden death due to e.g. coronary 
occlusion [113, 114]. 
As it has previously not been possible to measure serotonin directly in the living 
human brain, attempts have been made to indirectly assess serotonin levels in the 
brain by examinations of the cerebro-spinal fluid (CSF). Samples of CSF can be 
collected by lumbar puncture, and the concentration of serotonin and its 
metabolite 5-HIAA in the sample is assumed to reflect the extracellular serotonin 
concentration in the brain. Decreased levels of 5-HIAA in CSF has been reported 
in depressed patients compared to healthy controls [115-117]. A relation 
between low CSF 5-HIAA and suicide risk was first reported from our 
department in the 1970´s [118]. 
Tryptophan depletion is a method used to decrease brain levels of serotonin. It 
has been shown that patients in remission from depression experience a transient 
return of depressive symptoms after acute tryptophan depletion [119, 120]. 
However,  consistent changes in mood after tryptophan depletion have not been 
shown in healthy subjects lacking risk factors for depression (for review see 
[121]. 
 
1.3.4 Antidepressants 
The first antidepressant drugs were, just as the antipsychotic drugs, discovered 
empirically during the 1950´s. Most of currently available antidepressants are 
affecting the serotonin system, preferentially by blocking the serotonin 
transporter or enzymes that degrade serotonin.  
The very first antidepressant drug, iproniazid, was initially used for treatment of 
tuberculosis. It was observed that patients with coexisting depression also 
improved their psychiatric symptoms during treatment with iproniazid [122]. 
Iproniazid was later shown to be an inhibitor of MAO (MAOI).  
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The second antidepressant drug, imipramine, was discovered to have 
antidepressive properties, when it was tested as an antipsychotic drug in patients 
with schizophrenia [122]. It was later discovered that imipramine, like other 
tricyclic antidepressants (TCAs), blocks the reuptake of both serotonin and 
noradrenalin, via inhibition of SERT/5-HTT and NET. TCAs also block 
muscarinic acetylcholine receptors, leading to unwanted atropine-like 
anticholinergic side effects, and are toxic in higher doses. 
As both MAOIs and TCAs have severe side effects, the entry of selective 
serotonin reuptake inhibitors (SSRIs) on the market in the 1980’s was well 
received. These drugs are less toxic than TCAs, and not associated with 
anticholinergic side effects. SSRIs will be further described below. 
In addition to the three major groups of antidepressants (i.e. TCAs, MAOIs and 
SSRIs) there are other antidepressant drugs with different combinations of 
effects on the transporters and receptors of the serotonin and noradrenaline 
systems. For example, antidepressant drugs that block both SERT/5-HTT and 
NET, but do not inhibit acetylcholine receptors have been developed (i.e. 
serotonin-noradrenaline reuptake inhibitors, SNRIs). There are also 
antidepressant drugs that affect serotonergic receptors without blocking 
monoamine transporters. For instance, mirtazapine inhibits 5-HT2- and 5HT3 
receptors, while agomelatin is a melatonin receptor agonist and a 5-HT2C 
receptor antagonist [17]. 
A general disadvantage with all of the above described antidepressants is that 
their therapeutic effect is not immediate. Usually about 2-4 weeks of treatment is 
required for an obvious antidepressive effect. Recently, a more immediate 
antidepressive effect has been reported after acute administration of low doses of 
the anesthetic drug ketamine. However, it has yet to be determined whether the 
antidepressive effect can be maintained for longer periods. Ketamine is a 
glutamate N-methyl-d-aspartate (NMDA) receptor antagonist. The exact 
mechanism behind the antidepressive effect of ketamine is unclear, but might be 
of importance for further understanding of the pathophysiology of depression 
and the development of more effective treatment options (for review see [123]).  
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1.3.4.1 SSRIs 
The first SSRI, zimelidine [124] was introduced on the market in 1982. 
Zimelidine was soon withdrawn, due to the occasional occurrence of Guillain-
Barré syndrome, a rare but serious side effect [125]. However, the development 
of zimelidine represented a milestone in rational drug development [126], and 
several other SSRIs were soon developed.   
Though widely used since the 1980´s, the exact mechanism underlying the 
antidepressive effect of SSRIs remains unclear. PET studies have confirmed that 
SSRIs bind to the serotonin transporter in clinical treatment [127, 128]. High 
occupancy of the serotonin transporter is achieved already after a single dose of 
an SSRI [129]. Yet, the antidepressive effect is not ensued until after several 
weeks of treatment. This clinical observation indicates that inhibition of SERT is 
not the immediate cause of the antidepressive effect of SSRIs. Despite decades 
of research on animal models, the downstream effects of SSRIs in the human 
brain are not fully understood.  
1.3.4.2 Escitalopram 
Escitalopram is an antidepressant drug, belonging to the group of SSRIs. 
Escitalopram is the isolated S-enantiomer of the racemic compound citalopram, 
which contains equal amounts of the S- and R-enantiomer. It has been shown 
that it is mainly the S-enantiomer that accounts for the pharmacological effect on 
5-HT reuptake inhibition. However, when equal doses of the S-enantiomers are 
administered, clinical efficacy seems to be superior for escitalopram compared to 
citalopram [130]. This has led to the hypothesis that the R-enantiomer may 
partly counteract the effect of the S-enantiomer on the serotonin transporter (for 
review see [131]). 
It is commonly believed that the clinical effect of SSRIs is initiated by an 
increase of serotonin levels in the synapse. However, as suitable markers for 
endogenous serotonin levels have not been available, empirical testing of this 
assumption has not been possible in human subjects. 
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1.4 THE AGING BRAIN 
Generally 
Undoubtedly, the human body changes with age, and the brain is no exception. 
During childhood and adolescence the brain matures, which is associated with 
changes in grey and white matter volumes [132], as well as neuronal densities 
and synaptic morphology [133]. 
There are also age-related changes in the brain during adulthood. For example, 
grey matter volume decreases with age [134]. However, it has been observed that 
the actual number of neurons is generally not decreasing. Rather, there seem to 
be age-related changes in the connections between neurons in some brain regions 
(For review see [135]). 
The monoamine systems 
The first in vivo study reporting a decline in cerebral D2 receptors with age was 
published in 1984 [136]. This finding has later been reproduced [137], and also 
several other mono-amine transporters and receptors have been shown to 
decrease by age. For example, declines have been reported for the D1dopamine 
receptor, the dopamine transporter (DAT) (for review see [138])  and the 
noradrenalin transporter (NET) [139]. 
Age-related changes in the cerebral serotonin system have also been described, 
and proposed to be associated with behavioral changes observed particularly in 
the elderly population [140, 141]. Though only a few in vivo studies have been 
published on the effect of age on the serotonin system in humans, age related 
reductions in 5-HT2A receptor binding [136, 142] and in serotonin transporter 
binding [143] have been described. The effect of age on 5-HT1A receptor 
availability is less clear [144]. Previously, only one in vivo study on the age 
effect on the 5-HT1B receptor has been published [145]. This study reported an 
age-related decline in 5-HT1B binding, but as no conventional correction was 
made for possible age-related changes in brain volume, the results cannot be 
viewed as conclusive. As the 5-HT1B receptor has been implicated in age-related 
diseases [47, 146], further understanding of the effect of normal aging on this 
receptor is of interest. 
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2 AIMS 
The general aim of the present thesis was to extend the understanding of the 
mechanisms of action of psychiatric drugs in the human brain. Study I and 
study II included PET examinations of an antipsychotic drug and an 
antidepressant drug, respectively. The methodology used in study II was 
further evaluated in study III and study IV.   
The specific aims were as follows: 
Study I: To examine whether pharmacokinetic differences between two 
formulations of the antipsychotic drug quetiapine, would translate into 
differences in central D2 dopamine receptor occupancy 
Study II: To assess whether a single dose of the antidepressant drug 
escitalopram has effect on the endogenous serotonin concentration in brain 
Study III: To evaluate the test-retest reliability of the radioligand 
[11C]AZ10419369 
Study IV: To examine age-related changes in the availability of cerebral 5-
HT1B receptors, as assessed with PET and the radioligand [11C]AZ10419369 
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3 MATERIALS AND METHODS 
All studies were approved by the local Ethics and Radiation Safety Committees. 
Studies I-III were also approved by the Medical Products Agency in Sweden, as 
were the original studies in study IV when applicable. All human subjects gave 
verbal and written informed consent before the study specific procedures were 
initiated.  
The monkey experiments in study II, were approved by the Animal Research 
Ethical Committee of the Northern Stockholm region and were performed 
according to local (Drn 4820/06-600) and international guidelines [147]. 
 
3.1 STUDY SUBJECTS 
All human subjects participating in study I-IV were healthy according to medical 
history and physical examination, including ECG, routine blood tests and MRI 
of the brain. Additionally, a urine drug screen was performed prior to inclusion 
and at the PET measurement day. Studies I-III included only male subjects, aged 
20-30 years, while study IV included both male and female subjects across a 
larger age span (20-73 years). 
Subjects in study I (n=11) were recruited from an AstraZeneca database of 
subjects that had expressed an interest to participate in clinical trials. Subjects in 
study II (n=10) and study III (n=8) were recruited by local advertisements. For 
study IV, data were pooled from subjects that had previously participated in PET 
examinations with the radioligand [11C]AZ10419369 (n=51). In this study, data 
from subjects previously participating in studies II and III were also included.  
In study II, three female cynomolgus monkeys (Macaca fascicularis) were 
examined. The monkeys were housed in the Astrid Fagreaus Laboratory of the 
Swedish Institute for Infectious Disease Control, Solna, Sweden, and were 
transported to the PET center on the day of the PET examinations. The monkeys 
weighed 3.3 – 5.1 kg and together participated in totally 14 PET measurements. 
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3.2 STUDY DRUGS  
3.2.1 Quetiapine 
Quetiapine (QTP) is a second-generation antipsychotic drug, which in addition 
has received approval for treatment of bipolar disorder, major depression and 
generalized anxiety disorder. The clinical effects are thought to be mediated both 
by QTP and its main active human metabolite nor-quetiapine [103]. While 
initially produced as an immediate release (IR) formula, more recently an 
extended release (XR) formula has been developed. Pharmacokinetic studies 
have shown that the exposure in terms of area under the curve (AUC) for the two 
formulations is comparable, when given in equivalent daily doses [148]. 
However, the XR formulation has a slightly lower peak plasma concentration 
(Cmax) than the IR formulation, and a longer half-life which allows for once-
daily dosing. In study I, QTP was administered to healthy subjects to assess if 
the previously described differences in pharmacokinetics between the IR and the 
XR formulations also translate into different brain exposure and time-course of 
central D2 receptor occupancy. 
 
3.2.2 Escitalopram 
Escitalopram is an antidepressive drug, belonging to the group of selective 
serotonin reuptake inhibitors (SSRIs). Escitalopram is considered to be among 
the most “selective” of the SSRIs [149]. Escitalopram was therefore the drug of 
choice in study II, where the aim was to assess the effect of a single dose SSRI 
on endogenous serotonin levels. The highest recommended dose for clinical 
treatment (20 mg) was chosen, as the dose was administered only once.  
 
3.3 PET EXAMINATIONS 
All PET examinations were performed using a High Resolution Research 
Tomograph (HRRT; Siemens Molecular Imaging, USA). The resolution of this 
system has been estimated to approximately 1.5 mm FWHM, when modeling of 
the point spread function is included in the image reconstruction [5].  
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Before initiation of the PET examinations, a plaster helmet was made 
individually for each human subject. The helmet was used during each PET 
measurement, to minimize head movements and to ensure maintenance of the 
same head positioning if the subject participated in more than one PET 
examination.  
Monkeys were anesthetized before insertion into the PET system, and their heads 
were immobilized with a fixation device. Monkeys were supervised throughout 
the PET measurements and monitored for vital parameters.  
For all human subjects, radioligands were injected intravenously (iv) as a bolus, 
followed by a rapid flush with 10 mL of physiological sodium chloride solution. 
Radioactivity in brain was measured in list mode fashion over 63 or 93 min, 
depending on the study specifications. The distribution of radioactivity from 
each PET measurement was reconstructed in 3D for a series of time frames 
consisting of eight 10-sec, five 20-sec, four 30-sec, four 1-min, four 3-min and 
seven 6-min frames for the 63 min measurement. For the 93 min measurement, 
the same initial sequences of frames were used, with the addition of five 6-min 
frames for the last 30 min.  
In monkeys, the radioligand was administered iv according to a bolus-infusion 
protocol. With this protocol, the radioligand was injected as a bolus, at the same 
time as continuous infusion with a pump was initiated. Radioactivity in the brain 
was measured in a list mode fashion over 123 minutes and reconstructed in a 
series of 26 time frames (three 1-min, six 3-min and seventeen 6-min frames).  
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3.3.1  Radioligands 
3.3.1.1 [11C]Raclopride 
[11C]Raclopride is the most commonly used radioligand for imaging of D2 
dopamine receptors [72]. Being a selective antagonist with moderately high 
affinity to the D2 receptor, [11C]raclopride is useful for imaging of brain regions 
with a high density of D2 receptors, such as the striatum [150]. [11C]Raclopride 
was used in study I, and prepared by methylation of the corresponding desmethyl 
precursor using [11C]methyl triflate, as previously described [151]. 
 
3.3.1.2 [11C]AZ10419369 
[11C]AZ10419369 is a recently developed radioligand that binds selectively to 5-
HT1B receptors [48, 51]. In study III, the test-retest reliability of PET imaging 
with [11C]AZ10419369 was studied. In study IV, [11C]AZ10419369 was used for 
quantification of 5-HT1B receptors in the brain.  
[11C]AZ10419369 has also proven useful to study regional changes in 
extracellular serotonin concentrations [55, 56], and it was used for this purpose 
in study II. In all three studies, [11C]AZ10419369 was prepared by N-
methylation of the corresponding desmethyl precursor using [11C]methyl triflate 
as previously described [48]. 
 
3.3.2 Image processing 
T1-weighted MR images were initially acquired using a 1.5 T Signa system and 
more recently a MR discovery 750 3T system (both systems from GE Medical 
Systems, Milwaukee, WI, USA). The 1.5 T Signa system was used for study I 
and part of study IV, and the 3 T system for studies II, III and most of study IV. 
The MR images were realigned so that the plane defined by the anterior-
posterior commissure was placed horizontally.  
In all studies, a region of interest (ROI) for the cerebellum was manually 
delineated on the realigned MR images for each subject, by means of Human 
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Brain Atlas software [152]. In studies I-III, all other ROIs were manually 
delineated in the same way. In study IV, a ROI template (the Automated 
Anatomical Labeling, AAL) [153] was used for definition of all ROIs except for 
the cerebellum.  
MR images were co-registered to averaged PET images using statistical 
parametric software (SPM 5, Wellcome Department of Cognitive Neuroscience, 
UK). PET data were corrected for motion using frame-by-frame motion 
correction as previously described [154]. ROIs were then transferred to the series 
of PET images to generate time-activity curves.  
 
3.3.2.1 Binding Potential and SRTM 
The brain radioactivity measured with PET represents both the radioligand 
molecules that are specifically bound to the target receptor, and the molecules 
that are either un-bound or bound to other off-target proteins (= non-displaceable 
radioligand). Mathematical models are needed to translate the measured 
radioactivity into different parameters that describe radioligand kinetics in the 
brain.  
In study I-IV, the binding potential (BP) was commonly used as such a 
parameter.  
 
The BP of the radioligand is a term that is equivalent to the product of the 
density of the target receptor (Bmax) and the binding affinity (1/Kd) [155]: 
 
  
dK
BBP max=   (1) 
An important note is that the Bmax and Kd cannot be separately determined in one 
PET measurement.   
BP can be calculated by different models. The Simplified Reference Tissue 
Model (SRTM) was used to calculate BP in studies I-IV [156]. With this 
method, a brain region devoid of the target receptor is used as a reference region. 
The reference region is assumed to contain the same concentration of the non-
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displaceable radioligand as the regions of interest. The binding potential derived 
with this method, the BPND [157], refers to the ratio between the concentration of 
the specifically bound radioligand and the concentration of the non-displaceable 
radioligand in tissue at equilibrium conditions. 
The human cerebellum has been shown to contain negligible densities of D2 and 
5-HT1B receptors [43, 158, 159]. The manually delineated cerebellum ROI was 
therefore for each subject used as the reference region in all studies.  
 
3.3.2.2 Occupancy 
In study I and study II, the aim was to compare radioligand binding before and 
after administration of the study drug. The drug-induced change in BPND was 
calculated according to the following equation:  
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Where Δ is the drug-induced change in BPND, baslineNDBP  is the BPND in the drug-
free state, and drugNDBP  is the BPND measured after drug administration. In study I, 
Δ represents D2 receptor occupancy by quetiapine and in study II Δ represents 5-
HT1B receptor occupancy by endogenous serotonin.  
 
3.3.2.3 Ki,app 
If assuming a linear relationship between drug concentration in plasma and in 
brain, the relationship between receptor occupancy and the plasma concentration 
of a drug can be described as: 
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Where Occmax is the maximal occupancy induced by the drug, Cp is the plasma 
concentration and Ki,app is an operationally defined affinity constant 
corresponding to the drug plasma concentration required to occupy 50% of the 
receptors.  
In study I, Ki,app was derived by fitting  equation 3 to measured values of receptor 
occupancy and plasma concentrations, using a non-linear least squares 
minimization procedure. Occmax was set to 100% , as previous studies have 
demonstrated that 100 % D2 receptor occupancy is approached for 
[11C]raclopride binding during treatment with high doses of antipsychotic drugs 
[160]. 
3.3.2.4  Partial Volume Effect correction (PVEc)  
In study IV, cortical volume was expected to differ between subjects, as the grey 
matter volume has been shown to decrease with age [134]. The Partial Volume 
Effect (PVE) is larger in smaller volumes, i.e. a larger percentage of the 
radioactivity is spilling out from the ROI. Thus, a correction for PVE was 
required in this study. The PVE correction (PVEc) method described by Meltzer 
et al [161] was used in study IV. This PVEc method is correcting for spill-out of 
radioactivity from brain tissue in to the CSF. Consequently, regions at a greater 
distance from the CSF border will not be corrected for, and regions with a large 
area adjoining the CSF will be more heavily corrected. 
 
3.4 STATISTICS 
In study I, a two-tailed, two-sample t-test was used to compare mean plasma 
concentrations and mean D2 receptor occupancy after administration of 
quetiapine XR and IR at peak and through concentrations.  
In study II, a two-tailed paired t-test was used to evaluate regional BPND values 
obtained at baseline and after escitalopram administration. The minimum level 
of significance was designated as p < 0.05 both for study I and study II.  
In study III, a t-test was not applicable for the main study purpose, i.e. to 
evaluate the test-retest-reliability of [11C]AZ10419369. Instead, descriptive 
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statistics were used to compare the BPND at PET 1 and PET 2. This included 
mean, standard deviation, coefficient of variation, difference (%), variability (%) 
and intraclass correlation coefficient (ICC).  
In study IV, a correlation analysis was performed for each ROI to determine the 
relationship between BPND and age. Multiple linear regression analysis was also 
performed with sex as covariate. The Bonferroni method was used to correct for 
multiple comparisons.  
The ICC in study III was calculated using SPSS version 20. All other statistical 
analyses were performed using SAS statistical software JMP 8 or 10 (SAS 
Institute, Cary, NC, USA). 
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4 RESULTS AND COMMENTS 
4.1 STUDY I: COMPARISION OF D2 DOPAMINE RECEPTOR 
OCCUPANCY AFTER ORAL ADMINISTRATION OF 
QUETIAPINE FUMARATE IMMEDIATE-RELEASE AND 
EXTENDED-RELEASE FORMULATIONS IN HEALTHY 
SUBJECTS 
Quetiapine (QTP) is an antipsychotic drug, produced in immediate-release (IR) 
and extended-release (XR) oral formulations. The primary aim of study I was to 
examine whether the pharmacokinetic differences described between the two 
formulations, translate into different time curves for central D2 dopamine 
receptor occupancy. Eleven healthy subjects were administered QTP XR and IR 
in a one-sequence cross-over fashion. Subjects were examined with PET and the 
radioligand [11C]raclopride at five occasions - at baseline, and after the last doses 
of quetiapine XR and IR at predicted times of peak and trough plasma 
concentrations (Figure 4). 
 
 
Figure 4: Schematic summary of the study design of study I 
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The BPND was calculated using SRTM, and the striatal D2 receptor occupancy at 
peak and trough concentrations of QTP were calculated for each subject. The 
peak D2 receptor occupancy was significantly higher after administration of the 
IR formulation compared to the XR formulation (IR: 50±4%; XR: 32±11%, p 
=0.0003). The trough D2 receptor occupancy was similarly low for both 
formulations (IR: 7±7%; XR: 8±6%, p=0.7) (Figure 5). 
 
 
 
Figure 5: D2 receptor occupancy after administration of quetiapine IR and XR, 
respectively 
 
The time curve for estimated D2 receptor occupancy during a dosing interval was 
also calculated for each formulation, using equation 3 as described in the 
Materials and Methods section.  After administration of the XR formulation, the 
peak D2 receptor occupancy was less pronounced and diminished slower over 
time after peak, than after administration of the IR formulation (Figure 6). 
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Figure 6: Estimated D2-dopamine receptor occupancy (%) versus time for 
quetiapine IR (left) and XR (right) formulations.  The solid lines describe the 
occupancy-time curve for a typical individual.  The grey areas represent the 
95% prediction intervals. 
 
In clinical practice, QTP IR is usually administered twice-daily for the treatment 
of schizophrenia. As the primary aim of study I was to achieve a direct 
comparison of the XR and IR formulation, IR was administered only once-daily. 
The calculated D2 receptor occupancy for the IR formulation can therefore not be 
directly translated to the more commonly used twice-daily dosing. The D2 
receptor occupancy associated with the standard 150 mg twice-daily treatment 
would in all probability be lower than the receptor occupancy in this study. 
However, larger fluctuation of the D2 receptor occupancy during the dosing 
interval with the IR compared to the XR formulation would still be expected.  
The lower peak receptor occupancy associated with quetiapine XR may explain 
previously observed pharmacodynamic differences between the formulations. 
Additionally, the results support the view that QTP may have antipsychotic 
effect at lower D2 receptor occupancy than previously described for first-
generation antipsychotic drugs.  
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4.2 STUDY II: EFFECT OF A SINGLE DOSE ESCITALOPRAM ON 
SEROTONIN CONCENTRATION IN THE NON-HUMAN AND 
HUMAN PRIMATE BRAIN 
The primary aim of study II was to examine whether a single dose of the 
antidepressant drug escitalopram affects endogenous serotonin levels in human 
brain.  
Initially, three monkeys were examined with PET and the 5-HT1B receptor-
selective radioligand [11C]AZ10419369, before and after administration of a high 
single dose of escitalopram (2.0 mg/kg, iv) (fig 3). When a measurable effect of 
escitalopram on the BPND of [11C]AZ10419369 in monkeys had been confirmed, 
the methodology was applied to human subjects using a lower, clinically relevant 
dose of escitalopram.  
Nine male healthy subjects between 20 and 30 years of age were examined in the 
study. Each subject participated in two PET measurements with 
[11C]AZ10419369: One in the morning during drug-free (baseline) conditions 
and one in the afternoon approximately 3 h after administration of a single oral 
dose of escitalopram (20 mg) (Figure 7).  
 
 
 
Figure 7: Schematic summary of the study design of study II  
 
The BPND of [11C]AZ10419369 for each PET measurement was defined in ROIs 
delineated for the raphe nuclei and for serotonergic projection areas. The 
difference in BPND between the pre- and post-dose PET measurements was used 
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as an index of the change in radioligand binding due to changes in extracellular 
serotonin levels.  
In human subjects, the BPND of [11C]AZ10419369 was increased in serotonergic 
projection areas after administration of escitalopram, indicating a decrease in the 
extracellular serotonin concentration. In the region defined for the raphe nuclei, 
there was on the contrary a trend to a decrease of the BPND (Figure 8).  
 
  
 
Figure 8: Relative change in regional BPND of [11C]AZ10419369 in human 
subjects after administration of escitalopram. FC = frontal cortex; OC = 
occipital cortex; TC = temporal cortex; CN = caudate nucleus; Put = putamen; 
Thal = thalamus; RN = raphe nuclei.  
 
This observation directly in human subjects extends previous hypotheses on the 
mechanism of action of antidepressant drugs, derived primarily from 
experimental animals.  The results are consistent with the hypothesis that an 
increase of serotonin in the raphe nuclei induces stimulation of serotonergic 
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autoreceptors, which in turn decreases the firing and release of serotonin in 
projection areas. The observation of a decrease of serotonin in serotonergic 
projection areas after administration of a single dose of escitalopram, may 
contribute to the understanding of the time-lag between SERT/5HTT occupancy 
and the onset of the clinical effect of SSRIs.  
 
4.3 STUDY III: TEST-RETEST RELIABILITY OF [11C]AZ10419369 
BINDING TO 5-HT1B RECEPTORS IN HUMAN BRAIN 
To further evaluate the methodology used in study II, the test-retest reliability of 
[11C]AZ10419369 binding was estimated in human subjects.  
Eight male healthy subjects between 20 and 30 years were examined twice on 
the same day with PET and [11C]AZ10419369, at baseline conditions.  
The timing of the PET measurements were chosen to equal the times of PET 1 
and 2 in study II, but for practical reasons the second PET measurement was 
performed 1 hour earlier than in study II (Figure 9).  ROIs were delineated for 
the raphe nuclei and serotonergic projection areas (i.e. frontal cortex, occipital 
cortex, temporal cortex, putamen and  thalamus).  
 
 
 
Figure 9: Schematic summary of the study design of study III 
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The BPND of [11C]AZ10419369 was calculated using SRTM. The BPND in each 
ROI at PET 1 and PET 2 was compared using descriptive statistics such as mean, 
SD, difference (%) and variability (%). Overall, there was a good agreement 
between individual BPND values at PET 1 and PET 2 in serotonergic projection 
areas (Figure 10). 
 
 
Figure 10: Relationship between individual BPND values at PET 1 and PET 2 in 
serotonergic projection areas. Each dot represents the value at PET 1 (x-axis) 
and PET 2 (y-axis) for one particular subject in one of the five regions. The solid 
line represents the line of identity for the BPND at PET 1 and PET 2 
 
The absolute mean differences in BPND between PET 1 and PET 2 was less than 
3 % in all regions examined except for the raphe nuclei. The absolute variability 
was low (5-7%) in cortical areas but higher (20%) in the raphe nuclei. 
The results support the interpretation of study II, i.e. that the increase in BPND in 
serotonergic projection areas observed in study II was indeed an effect of the 
escitalopram administration. The higher test-retest variability in the raphe nuclei 
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serves as a possible explanation for why it was difficult to obtain conclusive 
evidence for an effect of escitalopram in this region (Figure 11).   
 
 
 
Figure 11: Comparison of results from study II and study III; change in BPND 
between PET 1 and PET 2 
 
On a more general level, it can be concluded that the BPND of [11C]AZ10419369 
is highly reproducible in cortical areas and satisfactory in the subcortical 
serotonergic projection regions measured. As the variability was substantially 
higher in the raphe nuclei, larger sample sizes or larger treatment- or condition-
related effects are required to assess a potential difference between subjects or 
between measurements in this region.   
 
4.4 STUDY IV: DISTINCT REGIONAL AGE EFFECTS ON 
[11C]AZ10419369 BINDING TO 5-HT1B RECEPTORS IN THE 
HUMAN BRAIN 
In this study, the effect of age on 5-HT1B receptor availability, as assessed by 
[11C]AZ10419369 binding, was examined in fifty-three healthy subjects, aged 
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between 20 and 73 years. The BPND in cortical and subcortical areas was 
calculated using the simplified reference tissue model (SRTM).  
The grey matter volume has been shown to decrease with age [134]. Due to the 
large age-difference between subjects in this study, cortical volume was 
expected to differ between subjects. Thus, a correction for PVE was required.  
The PVEc method described by Meltzer et al [161], was used in study IV. Other 
methods for PVEc could also have been considered. While the Meltzer method 
corrects for spill-out of radioactivity from brain tissue in to the CSF, the PVEc 
method described by Rousset et al [162] corrects also for spillover between brain 
regions. While this method probably provides a more thorough and 
“widespread” PVE correction, the lack of validation in our systems with the 
[11C]AZ10419369 radioligand made it unsuitable for the present study. 
A third PVEc method has been described by Muller-Gartner [163]. In this 
method, PVEc are made both for spillover to CSF and between grey and white 
matter. While this last step might seem as an improvement compared to the 
method described by Meltzer, the Muller-Gartner method assumes that the 
radioligand is evenly distributed within white respective grey matter regions. As 
radioligand pharmacokinetics in white matter can be markedly various within 
brain regions, this method might introduce errors in the quantification of data. 
Thus, the Meltzer method was considered the best option, although not free from 
disadvantages.  
After correction for PVE, the correlation between age and regional BPND was 
examined. 5-HT1B receptor availability decreased significantly with age in 
cortical regions, with an average decrease of 8 % per decade. In the ventral 
striatum, the age-related decrease was smaller (4% per decade). On contrary, the 
5-HT1B receptor availability in the dorsal striatal regions, the caudate nucleus 
and putamen, remained stable over age (Figure 12).  
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Figure 12: Correlation between regional BPND and age. Each dot represents the 
BPND and age of one individual subject in the brain region specified in the 
figure. CAU = caudate nucleus, PUT = putamen, VST = ventral striatum. 
 
The findings support previous reports of decreases in biomarkers for cerebral 
monoaminergic neurotransmitter systems by age. The stable 5-HT1B receptor 
availability in the caudate nucleus and the putamen is intriguing, and might 
indicate that 5-HT1B receptors in these regions are expressed on neurons with a 
different sensitivity to aging.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
Study I: The lower peak D2 receptor occupancy associated with quetiapine 
(QTP) XR compared to QTP IR may explain previously observed 
pharmacodynamic differences between the formulations. Further, the study 
provided additional support for the view that quetiapine, like clozapine, could 
have antipsychotic effect at lower D2 receptor occupancy levels than the 
previously suggested therapeutic window.  
While the lower D2 receptor occupancy could explain the lower propensity for 
EPS with these drugs, the mechanism behind a possibly maintained 
antipsychotic effect despite moderate D2 receptor occupancy remains to be 
elucidated. Hypothetically, this could be due to effects also on other receptor 
systems.  
The different shapes of the estimated D2 receptor occupancy time curves during 
a dosing interval with QTP XR compared to IR, also highlights the lack of 
knowledge regarding the relationships between duration of high D2 occupancy 
and antipsychotic effect.  
Both of the above mentioned issues need to be considered, for future 
development of antipsychotic drugs with improved efficacy and less side-effects. 
Further knowledge on the relationship between duration of D2 receptor 
occupancy and antipsychotic effect, could also aid in optimizing the dosing of 
already available antipsychotic drugs.  
Study II: Hypothetically, SSRIs initiate their clinical effect by increasing the 
serotonin concentration in the synapse. The results from study II indicate that 
extracellular serotonin levels in serotonergic projection areas decrease after a 
single, clinically relevant dose of an SSRI in human subjects. This observation 
may contribute to the understanding of the time-lag between SERT/5-HTT 
occupancy and clinical effect. However, further in vivo studies in humans are 
needed to evaluate the effect of SSRIs on extracellular serotonin concentrations 
after prolonged treatment, and whether there is a correlation between changes in 
serotonin concentrations and antidepressive effect. It would also be of interest to 
further examine the other downstream effects of SSRI treatment. Possibly this 
could aid in the development of antidepressant drugs with improved 
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effectiveness and with a shorter time-lag before the onset of the desired clinical 
effect. 
Study III: A high reproducibility between repeated measurements of the BPND of 
the radioligand [11C]AZ10419369, was demonstrated in serotonergic projection 
areas. This observation support the interpretation of the results of study II - i.e. 
that the change in BPND in serotonergic projection areas after escitalopram 
administration was indeed caused by escitalopram. However, the larger 
variability of the BPND  in the area defined for the raphe nuclei, indicates the need 
for improved methodology for measurement of 5-HT1B receptors in this region. 
As it is not possible to delineate the exact anatomical boundaries of the raphe 
nuclei on MR images, a more functionally based delineation directly on the PET 
images could be useful. This kind of delineation could be implemented if the 
distribution of [11C]AZ10419369 within the raphe nuclei is sufficiently high 
compared to the surrounding tissue. However, this strategy has not yet been 
evaluated. Until then, larger sample sizes or larger effect sizes are required to 
assess a potential difference between subjects or between measurements in this 
region.   
Study IV: The 5-HT1B receptor availability, as assessed with PET and 
[11C]AZ10419369, decreased significantly with age in cortical regions, but the 5-
HT1B receptor availability in the caudate nucleus and the putamen remained 
stable over the investigated age range. This observation might indicate that the 5-
HT1B receptors in the caudate nucleus and the putamen are expressed on neurons 
with a different sensitivity to aging. Further studies are needed to examine the 
fraction of pre- and post-synaptic expression of the 5HT1B receptor in different 
brain regions.  
The results from study IV also highlight the importance of using age-matched 
control subjects in future studies of the 5-HT1B receptor. It remains to be 
clarified whether the age-related decline in 5-HT1B receptor availability is related 
to changes in behavioral and cognitive functions in normal aging, or in relation 
to CNS disorders. 
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